Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1871797 | 0.94 | POLB (0.56) | HTR1AHTR2ATSHRUSP2KDM4E | |
| SCHEMBL17443426 | 0.82 | KDM4E (0.69) | HTR2ACYP2D6TSHRUSP2KDM4E | |
| SCHEMBL1871010 | 0.81 | KDM4E (0.59) | HTR1AHTR2ACYP2D6TSHRKDM4E | |
| SCHEMBL9972739 | 0.80 | KDM4E (0.61) | TSHRUSP2KDM4ETDP1SMN1; SMN2 | |
| SCHEMBL27587584 | 0.78 | USP2 (0.59) | HTR1AHTR2ACYP2D6TSHRUSP2 | |
| SCHEMBL4265430 | 0.78 | KDM4E (0.63) | CYP2D6TSHRUSP2KDM4ETDP1 | |
| SCHEMBL4399410 | 0.77 | KDM4E (0.65) | CYP2D6TSHRUSP2KDM4ETDP1 | |
| SCHEMBL2062605 | 0.77 | KDM4E (0.65) | CYP2D6TSHRUSP2KDM4ETDP1 | |
| SCHEMBL31661824 | 0.77 | KDM4E (0.65) | CYP2D6TSHRUSP2KDM4ETDP1 | |
| SCHEMBL31661823 | 0.77 | KDM4E (0.65) | CYP2D6TSHRUSP2KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962627-B2 | Oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors | PRESTWICK CHEMICAL, INC. (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8962627-B2 | Oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors | PRESTWICK CHEMICAL, INC. (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8962627-B2 | Oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors | PRESTWICK CHEMICAL, INC. (FR) | 2015-02-24 | — | — | US | disclosed |
| EP-2493871-B1 | NOVEL OXIME DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2014-09-03 | — | — | EP | disclosed |
| EP-2493871-B1 | NOVEL OXIME DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2014-09-03 | — | — | EP | disclosed |
| US-20120277212-A1 | Novel Oxime Derivatives and Their Use As Allosteric Modulators of Metabotropic Glutamate Receptors | PRESTWICK CHEMICAL, INC. (FR) | 2012-11-01 | — | — | US | disclosed |
| US-20120277212-A1 | Novel Oxime Derivatives and Their Use As Allosteric Modulators of Metabotropic Glutamate Receptors | PRESTWICK CHEMICAL, INC. (FR) | 2012-11-01 | — | — | US | disclosed |
| US-20120277212-A1 | Novel Oxime Derivatives and Their Use As Allosteric Modulators of Metabotropic Glutamate Receptors | PRESTWICK CHEMICAL, INC. (FR) | 2012-11-01 | — | — | US | disclosed |
| WO-2011051478-A1 | NOVEL OXIME DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277212-A1 | Novel Oxime Derivatives and Their Use As Allosteric Modulators of Metabotropic Glutamate Receptors | GRM4, GRM1, GRM2 | HTR1A 202/4885HTR2A 260/4885CYP2D6 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.